Reasoning a Plant

Almost no herb has been tested in people the way a drug is. The usual reactions are to trust tradition or to dismiss everything. There is a third option, and it is the one I learned this autumn in a course on molecular biology: go one level down. Which molecule is in the plant, which protein does it touch, what does that protein do in the cell, what follows in the body, and what has been seen in a person? Each of these has its own kind of proof. Keep them apart and you can reason about a plant without a trial, and you know exactly where you are guessing. This lesson does that with one plant, barberry.

Why the trial is missing

A clinical trial costs a great deal of money, and whoever pays for it wants to own the result. A molecule can be patented. A plant that grows in a ditch cannot be owned in the same way. That is an argument about incentives, not a proven law, and there are exceptions: good small trials exist for several herbs. But it explains the pattern, and it explains why the absence of a trial is not the same as the absence of an effect. It is also not evidence of one.

The chain of five links

A chain is only as strong as its weakest link. Most claims about herbs jump from link 2 to link 5 and do not say so. Barberry is a good teacher because links 2 and 3 are well studied, link 5 has real trials, and link 1 is where it gets interesting.

Link 1: the yellow molecule

Barberry (Berberis vulgaris) is a thorny shrub. Cut the root or the inner bark and the wood is bright yellow. The yellow is berberine, an alkaloid that also sits in goldenseal, Oregon grape, tree turmeric (Berberis aristata) and the Chinese herb huanglian (Coptis chinensis). The berries are a different material from the root, and I could not find a verified figure for how much berberine each holds. Every dose in this lesson therefore refers to the trial product, not to a cup of tea.

Links 2 and 3: what it does inside the cell

In muscle cells and isolated mitochondria, berberine slowed complex I, the first enzyme complex of the respiratory chain, the same complex that metformin acts on (Turner et al., Diabetes 2008). The cell then makes slightly less energy. It carries its own energy meter, an enzyme called AMPK, which switches on when the used-up form of fuel piles up and moves the cell from spending to saving. Lee and colleagues (Diabetes 2006) saw AMPK activity rise in fat and muscle cells, sugar transporters move to the cell surface, and glucose handling improve in diabetic mice and in rats on a high-fat diet.

A second mechanism has been described in liver cells: berberine stabilises the messenger RNA of the LDL receptor, so cells carry more receptors and clear more LDL cholesterol from the blood (Kong et al., Nature Medicine 2004; hamsters, liver cells, and 32 patients treated for three months). That patient group has no control group in the abstract.

Level: model. Cells and rodents. It tells you where to look, and that is all.

Link 5: what happened in people

An early pilot (Yin et al., Metabolism 2008) gave 36 newly diagnosed patients berberine or metformin, 0.5 g three times a day for three months; the glucose effect was similar. A separate randomized trial gave 116 patients with type 2 diabetes and abnormal blood fats 1 g berberine a day or placebo for three months, and HbA1c fell from 7.5 to 6.6 percent in the berberine group (Zhang et al., JCEM 2008). Meta-analyses pool such trials: 37 trials and 3,048 people gave an HbA1c reduction of 0.63 percentage points and a fasting glucose reduction of 0.82 mmol/L (Xie et al., 2022). An earlier analysis of 28 studies (Liang et al., 2019) found that the effect became unremarkable beyond 90 days, above 2 g a day, and in patients over 60. Nobody has explained that.

Three caveats go with this. I read the abstracts of these analyses, not the full trials, and cannot grade the quality of the individual trials myself. Nearly all of this is purified berberine, not the plant. And the plant itself has been tested: 9 randomized trials with 547 patients using B. vulgaris or B. integerrima found a smaller drop in HbA1c (0.30 points), no clear change in weight or body mass index (Hussain et al., 2024). A trial in 84 people with high blood pressure used 10 g of dried barberries a day and found better blood vessel dilation after eight weeks (Emamat et al., 2021). Berries, not root.

Link 1 again: the weak spot

After a single 500 mg dose of standard berberine, made from barberry root, the blood level in 10 volunteers peaked at about 1.7 nanograms per millilitre (Solnier et al., Pharmaceutics 2023). That is almost nothing. A review of its pharmacokinetics explains why: the gut wall breaks much of it down, a pump pushes it back out, the liver clears the rest, and the gut bacteria turn it into other active compounds (Murakami et al., 2023, mostly from rat data). Yet it moves glucose and cholesterol in trials.

Three explanations are on the table. It may accumulate in tissues. Its metabolites may do some of the work. Or it may act in the gut wall itself. The third has a new answer: in mice, the glucose-lowering effect of both metformin and berberine depended on blocking complex I in the cells of the intestine (Sebo et al., Nature Metabolism 2026). If that holds in people, the low blood level is not a problem. It is the point. It is also one group, one species, and a few months old.

A mechanism also warns you

Knowing the biology gives you more than hope. It lets you predict harm before the case reports arrive. Berberine blocked the liver enzyme CYP2D6 in the test tube, with a half-maximal inhibition at 7.4 micromolar, the most sensitive of the three enzymes tested; the authors judged a relevant interaction unlikely in general, with CYP2D6 the possible exception (Zhao et al., 2012). That enzyme clears many common drugs, so the sensible question is whether you take one. Berberine also pushed bilirubin off its carrier protein in the test tube and raised unbound bilirubin in rats, which is why it is best avoided in jaundiced newborns and in pregnancy (Chan, 1993). In the early pilot, about a third of the patients had temporary stomach complaints. And anyone using medicine for diabetes should know the effects add up: ask the prescriber first.

Test tube and rats. Nobody ran a trial and nobody should have to. The link is sound enough to act on as a precaution.

Mouse is not human

The same lesson from a different plant. Gymnemic acids from Gymnema sylvestre block the human sweet taste receptor, a protein pair called T1R2 and T1R3. In a cell experiment they docked in a pocket inside the membrane part of T1R3 and did not work on the mouse receptor (Sanematsu et al., Journal of Biological Chemistry 2014). A mouse study would have missed the plant completely. In a small randomized crossover trial of 32 adults with a sweet tooth, gymnema mints taken as desired for 14 days lowered sugar-sweetened drinks by 42 percent and sugar cravings by 28 percent compared with placebo mints (Appetite 2025). Mechanism, species difference and human result line up here, which is rare. It is still 32 people for two weeks.

Four levels of certainty

Solid: purified berberine lowers HbA1c and fasting glucose in people with type 2 diabetes, in randomized trials pooled in meta-analyses. The direction is clear; the size and the quality of the single trials are not graded here.

Model: that it does so by slowing complex I and switching on the cell's energy meter (cells and rodents), and that the gut wall is where it acts (mice).

Thin: that the whole root or the berries, taken as tea or powder, do the same. Nine small trials with a smaller effect, and an unknown berberine content.

Not supported: that it "starves unwanted cells", that it "cleanses the lymphatic system", or that the 2008 trial with metformin and the 2008 trial with 116 patients were one and the same.

Five questions for any plant claim

1. What exactly is claimed? Turn "supports" and "balances" into something that could be measured.
2. In what system was it seen: a dish of cells, a mouse, a person? Every step away from a person costs certainty.
3. Was something done on purpose, and does more give more? Or did two things merely happen together?
4. Did someone else see it, with a different method?
5. What else could explain it, and who gains if you believe it?

Where this site got it wrong

I put these questions to my own pages while preparing this lesson, and some failed. One page described berberine as something that "starves unwanted cells", with no source behind it. Another credited a 2008 trial that compared berberine with metformin to the wrong paper: the metformin comparison had 36 patients (Yin), while the 116-patient trial (Zhang) used placebo. The protocol page cites both facts under one reference number. Those pages have been corrected.

What this lesson does not claim

It does not claim that barberry is a treatment for diabetes, high cholesterol or anything else, that tea or powder from the root gives the effect seen in trials with the purified pill, that the gut-wall mechanism is proven in people, or that reasoning replaces a trial. Reasoning tells you where the evidence is strong and where it is not. It does not tell you to skip a doctor, and anyone using medicines for blood sugar, blood pressure, depression or heart disease, or who is pregnant or breastfeeding, should ask first.

Sources

1. Turner N, Li JY, Gosby A, et al. "Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action." Diabetes 2008;57:1414–1418. PMID 18285556.
2. Lee YS, Kim WS, Kim KH, et al. "Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states." Diabetes 2006;55:2256–2264. PMID 16873688.
3. Kong W, Wei J, Abidi P, et al. "Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins." Nature Medicine 2004;10:1344–1351. PMID 15531889.
4. Sebo ZL, Chakrabarty RP, Grant RA, et al. "Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control." Nature Metabolism 2026;8. PMID 42103929.
5. Yin J, Xing H, Ye J. "Efficacy of berberine in patients with type 2 diabetes mellitus." Metabolism 2008;57:712–717. PMID 18442638.
6. Zhang Y, Li X, Zou D, et al. "Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine." Journal of Clinical Endocrinology and Metabolism 2008. PMID 18397984.
7. Xie W, Su F, Wang G, et al. "Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis." Frontiers in Pharmacology 2022. PMID 36467075.
8. Liang Y, Xu X, Yin M, et al. "Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis." Endocrine Journal 2019. PMID 30393248.
9. Hussain HU, Ali E, Tanveer A, et al. "Efficacy of Berberis vulgaris and Berberis integerrima on glycemic indices and weight profile in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials." Journal of Ayurveda and Integrative Medicine 2024. PMID 39413550.
10. Emamat H, Asadian S, Zahedmehr A, et al. "The effect of barberry (Berberis vulgaris) consumption on flow-mediated dilation and inflammatory biomarkers in patients with hypertension: a randomized controlled trial." Phytotherapy Research 2021. PMID 33350540.
11. Solnier J, Zhang Y, Kuo YC, et al. "Characterization and pharmacokinetic assessment of a new berberine formulation with enhanced absorption in vitro and in human volunteers." Pharmaceutics 2023. PMID 38004546.
12. Murakami T, Bodor E, Bodor N. "Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1." Expert Opinion on Drug Metabolism & Toxicology 2023. PMID 37057922.
13. Zhao Y, Hellum BH, Liang A, Nilsen OG. "The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine." Phytotherapy Research 2012. PMID 21678521.
14. Chan E. "Displacement of bilirubin from albumin by berberine." Biology of the Neonate 1993. PMID 8513024.
15. Sanematsu K, Kusakabe Y, Shigemura N, et al. "Molecular mechanisms for sweet-suppressing effect of gymnemic acids." Journal of Biological Chemistry 2014. PMID 25056955.
16. "The effect of a 14-day Gymnema sylvestre intervention to reduce sugar intake in people self-identifying with a sweet tooth." Appetite 2025. PMID 39855349.
17. Caesar LK, Cech NB. "Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2." Natural Product Reports 2019;36:869–888. PMID 31187844.
18. Own working notes: molecular biology knowledge base, module 06 (framework for testing a claim, own synthesis), and hotw_berberis_onderzoek.md. The abstracts above were read; full texts were not graded for risk of bias.